<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00047138</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000257531</org_study_id>
    <secondary_id>SIOP-WT-2001</secondary_id>
    <secondary_id>SFOP-SIOP-WT-2001</secondary_id>
    <secondary_id>CCLG-SIOP-WT-2001</secondary_id>
    <secondary_id>GPOH-GERMANY-SIOP-WT-2001</secondary_id>
    <secondary_id>EU-20208</secondary_id>
    <nct_id>NCT00047138</nct_id>
  </id_info>
  <brief_title>Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor</brief_title>
  <official_title>Nephroblastoma (Wilms Tumour) Clinical Trial And Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leicester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Societe Francaise Oncologie Pediatrique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Cancer and Leukaemia Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Giving combination chemotherapy before surgery may shrink the tumor&#xD;
      so it can be removed during surgery. Giving more chemotherapy after surgery may kill any&#xD;
      remaining tumor cells. It is not yet known which chemotherapy regimen after surgery is most&#xD;
      effective in treating Wilm's tumor.&#xD;
&#xD;
      PURPOSE: Phase III trial to study the effectiveness of chemotherapy before and after surgery&#xD;
      in treating children who have Wilm's tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate in children with Wilms' tumor treated with pre-operative&#xD;
           chemotherapy.&#xD;
&#xD;
        -  Compare the response rate in children with intermediate-risk stage II or III Wilms'&#xD;
           tumor treated with or without doxorubicin after surgery.&#xD;
&#xD;
        -  Determine the prognostic significance of histological subtypes in these patients after&#xD;
           pre-operative chemotherapy.&#xD;
&#xD;
        -  Determine whether reduced treatment minimizes acute and late toxicity without&#xD;
           jeopardizing event-free and overall survival in patients with focal anaplasia or&#xD;
           intermediate-risk stage I Wilms' tumor.&#xD;
&#xD;
        -  Determine the prognostic significance of tumor volume and specimen weight after&#xD;
           pre-operative chemotherapy and its relation to histological subtype in these patients.&#xD;
&#xD;
        -  Determine the effect of single-dose dactinomycin as pre-operative chemotherapy in these&#xD;
           patients.&#xD;
&#xD;
        -  Correlate allele loss at 16q, 1p, and other chromosomal regions with relapse-free and&#xD;
           overall survival of patients treated with these regimens.&#xD;
&#xD;
        -  Correlate allele losses with clinical risk factors (e.g., histological appearance and&#xD;
           tumor volume) after pre-operative chemotherapy in these patients.&#xD;
&#xD;
        -  Determine laboratory indicators of myocardial damage in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  Determine the prognostic significance of the percentage of necrosis after pre-operative&#xD;
           chemotherapy, in terms of type and amount of residual viable tumor, in these patients.&#xD;
&#xD;
      OUTLINE: This is a partially randomized, multicenter study. Patients are stratified according&#xD;
      to country and participating center. Patients with intermediate-risk stage II or III disease&#xD;
      are further stratified according to histology (blastemal vs epithelial vs stromal vs mixed).&#xD;
&#xD;
      Patients with localized disease receive neoadjuvant therapy comprising vincristine IV on days&#xD;
      1, 8, 15, and 22 and dactinomycin IV on days 1 and 15.&#xD;
&#xD;
      Patients undergo surgery during weeks 5 or 6.&#xD;
&#xD;
      Patients with low-risk stage I disease receive no further therapy.&#xD;
&#xD;
      Adjuvant chemotherapy begins after surgery and within 21 days of last dose of neoadjuvant&#xD;
      chemotherapy.&#xD;
&#xD;
      Patients with intermediate-risk stage I disease receive vincristine IV on days 1, 8, 15, and&#xD;
      22 and dactinomycin IV on day 7.&#xD;
&#xD;
      Patients with intermediate-risk stage II or III disease are randomized to 1 of 2 treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients receive vincristine IV weekly for 8 weeks and then on days 1 and 7 of&#xD;
           weeks 11, 14, 17, 20, 23, and 26. Patients also receive dactinomycin IV weekly on weeks&#xD;
           2, 5, 8, 11, 14, 17, 20, 23, and 26 and doxorubicin IV over 4-6 hours weekly on weeks 2,&#xD;
           8, 14, 20, and 26.&#xD;
&#xD;
        -  Arm II: Patients receive vincristine and dactinomycin as in arm I. Patients with&#xD;
           high-risk stage I disease receive chemotherapy as in arm I. Patients with low-risk stage&#xD;
           II disease receive chemotherapy as in arm II.&#xD;
&#xD;
      Patients with high-risk stage II or III disease receive cyclophosphamide IV over 1 hour on&#xD;
      days 1-3 and doxorubicin IV over 4-6 hours on day 1 on weeks 1, 7, 13, 19, 25, and 31.&#xD;
      Patients also receive etoposide IV over 4 hours and carboplatin IV over 1 hour on days 1-3 on&#xD;
      weeks 4, 10, 16, 22, 28, and 34.&#xD;
&#xD;
      Patients with intermediate-risk stage III or high-risk stage II or III disease also undergo&#xD;
      radiotherapy for approximately 3 weeks during chemotherapy.&#xD;
&#xD;
      Patients with metastatic disease receive neoadjuvant chemotherapy comprising vincristine IV&#xD;
      on day 1 of weeks 1-6, dactinomycin IV on day 1 of weeks 1, 3, and 5, and doxorubicin IV over&#xD;
      4-6 hours on day 1 of weeks 1 and 5.&#xD;
&#xD;
      Patients undergo surgery during week 7.&#xD;
&#xD;
      Within 2 weeks of surgery patients receive 1 of the following adjuvant chemotherapy regimens:&#xD;
&#xD;
        -  Regimen A (no metastases or completely resected): Patients receive vincristine IV weekly&#xD;
           for 8 weeks and then on weeks 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, and 27.&#xD;
           Patients also receive dactinomycin IV on day 1 of weeks 2, 5, 8, 11, 14, 17, 20, 23, and&#xD;
           26 and doxorubicin IV over 4-6 hours on weeks 2, 8, 14, and 20. Some patients also&#xD;
           undergo radiotherapy concurrently with chemotherapy for approximately 3 weeks.&#xD;
&#xD;
        -  Regimen B (multiple inoperable metastases, incomplete resection, or high-risk primary&#xD;
           disease): Patients receive etoposide IV over 4 hours and carboplatin IV over 1 hour on&#xD;
           days 1-3 of weeks 4, 10, 13, 16, 22, 25, 28, and 34. Patients also receive&#xD;
           cyclophosphamide IV over 1 hour on days 1-3 and doxorubicin IV over 4-6 hours on day 1&#xD;
           of weeks 1, 7, 19, and 31. Some patients also undergo radiotherapy concurrently with&#xD;
           chemotherapy for approximately 3 weeks.&#xD;
&#xD;
      Patients are followed every 2-3 months for 2 years, every 3-6 months for 1-2 years, and then&#xD;
      every 6-12 months thereafter.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 350 patients (174 per treatment arm) will be accrued for the&#xD;
      randomized portion of this study within 7 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2001</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment failure, in terms of disease recurrence or death</measure>
  </primary_outcome>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>dactinomycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of one of the following:&#xD;
&#xD;
               -  Localized disease&#xD;
&#xD;
                    -  Unilateral tumor&#xD;
&#xD;
                    -  Histologically confirmed Wilms' tumor OR&#xD;
&#xD;
                    -  Clinical and ultrasonic characteristics of nephroblastoma&#xD;
&#xD;
                    -  No metastasis&#xD;
&#xD;
                    -  Age 6 months to 17 years at diagnosis&#xD;
&#xD;
                    -  No prior anticancer therapy&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
                    -  Unilateral tumor&#xD;
&#xD;
                    -  Histologically confirmed Wilms' tumor OR&#xD;
&#xD;
                    -  Clinical and ultrasonic characteristics of nephroblastoma&#xD;
&#xD;
                    -  Age 18 and under&#xD;
&#xD;
                    -  No prior anticancer therapy&#xD;
&#xD;
               -  Simultaneous bilateral tumors&#xD;
&#xD;
                    -  No metastases&#xD;
&#xD;
          -  No recurrent disease&#xD;
&#xD;
          -  No other renal tumors&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  18 and under&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No social or geographical reasons that would preclude study&#xD;
&#xD;
          -  No other associated pathology that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior surgery&#xD;
&#xD;
          -  No requirement for emergency or immediate surgery for any reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan DeKraker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francois Pein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathy Pritchard-Jones, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Graf</last_name>
    <role>Study Chair</role>
    <affiliation>Universitaetsklinikum des Saarlandes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805 CEDEX</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Pein, MD</last_name>
      <phone>33-1-4211-4339</phone>
      <email>pein@igr.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert Graf</last_name>
      <phone>49-6841-162-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum at University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1100 DE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan DeKraker, MD</last_name>
      <phone>31-20-566-9111</phone>
      <email>j.dekraker@amc.uva.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Pritchard-Jones, MD</last_name>
      <phone>44-20-8661-3452 ext 3498</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Warmann SW, Nourkami N, Frühwald M, Leuschner I, Schenk JP, Fuchs J, Graf N. Primary lung metastases in pediatric malignant non-Wilms renal tumors: data from SIOP 93-01/GPOH and SIOP 2001/GPOH. Klin Padiatr. 2012 Apr;224(3):148-52. doi: 10.1055/s-0032-1304600. Epub 2012 Apr 18.</citation>
    <PMID>22513793</PMID>
  </reference>
  <reference>
    <citation>Furtwängler R, Nourkami N, Alkassar M, von Schweinitz D, Schenk JP, Rübe C, Siemer S, Leuschner I, Graf N. Update on relapses in unilateral nephroblastoma registered in 3 consecutive SIOP/GPOH studies - a report from the GPOH-nephroblastoma study group. Klin Padiatr. 2011 May;223(3):113-9. doi: 10.1055/s-0031-1275293. Epub 2011 Apr 20.</citation>
    <PMID>21509706</PMID>
  </reference>
  <reference>
    <citation>van den Heuvel-Eibrink MM, van Tinteren H, Rehorst H, Coulombe A, Patte C, de Camargo B, de Kraker J, Leuschner I, Lugtenberg R, Pritchard-Jones K, Sandstedt B, Spreafico F, Graf N, Vujanic GM. Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: a report of the SIOP renal tumour study group. Pediatr Blood Cancer. 2011 May;56(5):733-7. doi: 10.1002/pbc.22922. Epub 2010 Dec 22.</citation>
    <PMID>21370404</PMID>
  </reference>
  <reference>
    <citation>Warmann SW, Furtwängler R, Blumenstock G, Armeanu S, Nourkami N, Leuschner I, Schenk JP, Graf N, Fuchs J. Tumor biology influences the prognosis of nephroblastoma patients with primary pulmonary metastases: results from SIOP 93-01/GPOH and SIOP 2001/GPOH. Ann Surg. 2011 Jul;254(1):155-62. doi: 10.1097/SLA.0b013e318222015e.</citation>
    <PMID>21670612</PMID>
  </reference>
  <reference>
    <citation>Szavay P, Luithle T, Graf N, Furtwängler R, Fuchs J. Primary hepatic metastases in nephroblastoma--a report of the SIOP/GPOH Study. J Pediatr Surg. 2006 Jan;41(1):168-72; discussion 168-72.</citation>
    <PMID>16410128</PMID>
  </reference>
  <results_reference>
    <citation>Smets AM, van Tinteren H, Bergeron C, De Camargo B, Graf N, Pritchard-Jones K, de Kraker J. The contribution of chest CT-scan at diagnosis in children with unilateral Wilms' tumour. Results of the SIOP 2001 study. Eur J Cancer. 2012 May;48(7):1060-5. doi: 10.1016/j.ejca.2011.05.025. Epub 2011 Jun 22.</citation>
    <PMID>21703848</PMID>
  </results_reference>
  <results_reference>
    <citation>Williams RD, Al-Saadi R, Chagtai T, Popov S, Messahel B, Sebire N, Gessler M, Wegert J, Graf N, Leuschner I, Hubank M, Jones C, Vujanic G, Pritchard-Jones K; Children's Cancer and Leukaemia Group; SIOP Wilms' Tumour Biology Group. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. Clin Cancer Res. 2010 Apr 1;16(7):2036-45. doi: 10.1158/1078-0432.CCR-09-2890. Epub 2010 Mar 23.</citation>
    <PMID>20332316</PMID>
  </results_reference>
  <results_reference>
    <citation>Messahel B, Williams R, Ridolfi A, A'hern R, Warren W, Tinworth L, Hobson R, Al-Saadi R, Whyman G, Brundler MA, Kelsey A, Sebire N, Jones C, Vujanic G, Pritchard-Jones K; Children's Cancer and Leukaemia Group (CCLG). Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study. Eur J Cancer. 2009 Mar;45(5):819-26. doi: 10.1016/j.ejca.2009.01.005. Epub 2009 Feb 21.</citation>
    <PMID>19231157</PMID>
  </results_reference>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>October 3, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>blastema predominant Wilms tumor</keyword>
  <keyword>epithelial predominant Wilms tumor</keyword>
  <keyword>mixed cell type Wilms tumor</keyword>
  <keyword>stage I Wilms tumor</keyword>
  <keyword>stage II Wilms tumor</keyword>
  <keyword>stage III Wilms tumor</keyword>
  <keyword>stage IV Wilms tumor</keyword>
  <keyword>stage V Wilms tumor</keyword>
  <keyword>stromal predominant Wilms tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Wilms Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dactinomycin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

